Medtronic plc (MDT) rises 5.6% after strong earnings
Medtronic plc (MDT) rises after posting fiscal Q4 and full-year FY2026 results that beat guidance and showed its strongest annual revenue growth in a decade. The company also raised its dividend and issued upbeat FY2027 guidance, helping investors reprice the stock as a faster-growing medtech name.
Medtronic plc (MDT) rose sharply after reporting fiscal Q4 and full-year FY2026 results that beat expectations and showed the company’s strongest annual revenue growth in 10 years. The rally was driven by stronger sales, upbeat FY2027 guidance, and standout growth in cardiac ablation, signaling that investors are beginning to view MDT as a more durable growth story with income support.
Medtronic plc (MDT) rises 5.63% to $77.90 on June 3, 2026, with volume running at 1.3x its 200-day average. The move stands out even more because the broader market is weaker today, which points to a company-specific catalyst rather than a simple sector lift.
Key Takeaways
MDT is jumping after reporting fiscal Q4 and full-year FY2026 results that beat guidance and showed its strongest annual revenue growth in 10 years.
The clearest catalyst is the June 3 earnings report: Q4 revenue reached $9.8B, up 9.9%, while non-GAAP EPS came in at $1.55.
FY2027 guidance added fuel, with Medtronic projecting 6.75% to 7.25% organic revenue growth and non-GAAP EPS of $5.90 to $6.00.
A dividend increase to $0.72 per share and FY2026 free cash flow of $5.4B reinforced the case for both growth and income investors.
For investors, the key shift is that MDT is being treated less like a slow, defensive medtech name and more like a large-cap company with improving growth.
The main reason Medtronic (MDT) is higher today is straightforward. The company reported fiscal Q4 and full-year FY2026 results on June 3, and the numbers were strong enough to reset the story.
Q4 revenue was $9.8B, up 9.9% as reported and 6.6% organic. Medtronic also posted GAAP diluted EPS of $0.96 and non-GAAP diluted EPS of $1.55, both ahead of its own guidance. For the full year, revenue reached $36.364B, up 8.4% reported and 5.8% organic. Management called that the strongest annual top-line growth in a decade, and the market clearly liked the sound of that.
Just as important, the company did not pair a good quarter with cautious guidance. Instead, Medtronic guided FY2027 organic revenue growth to 6.75% to 7.25% and non-GAAP EPS to $5.90 to $6.00. That is the kind of outlook that can push a mature healthcare stock higher because it tells investors the quarter was not a one-off.
There was also a shareholder-friendly bonus. The board raised the quarterly dividend to $0.72 from $0.71, marking Medtronic's 49th straight year of dividend increases. In plain English, the company delivered growth, lifted its outlook, and still had enough cash confidence to raise the payout.
Medtronic's Cardiac Ablation Growth Is Driving the Rerating
Not all earnings beats are equal. What matters here is where the growth came from. Medtronic's Cardiac Ablation Solutions business surged 78% globally, including 124% growth in the U.S. The company also said it gained 8 points of U.S. share in that category.
That matters because electrophysiology and ablation are high-value areas in medtech. They are also areas where investors reward share gains more than simple stability. Medtronic highlighted momentum from its Affera platform and related pipeline assets, which helps explain why the market treated this report as more than a routine beat.
The strength was not isolated to one pocket of the business either. Cardiovascular revenue grew 10.1%, and Medical Surgical revenue rose 5.1%. That broader base matters. A single hot product can excite traders for a day. Multi-segment growth gets institutions involved, and that is usually where above-average volume comes from.
MDT's intraday range also fits an earnings-driven repricing. The stock traded between $73.06 and $79.09 during the session after the early morning results were posted. That kind of gap-and-run action usually means the market is adjusting to new information fast, not just drifting on sentiment.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
How Medtronic plc's Financials Look After the Move
Even after today's jump, Medtronic still looks more balanced than stretched. The stock trades at a P/E of 20.6, carries a market cap of about $100.01B, and offers a 3.83% dividend yield. That is not a bargain-bin multiple, but it is also not an extreme valuation for a large medical device company posting its best annual revenue growth in 10 years.
Cash generation adds another layer of support. Medtronic produced $7.3B in operating cash flow and $5.4B in free cash flow in FY2026. Those figures matter because they support the dividend, fund product investment, and give the company room to keep pushing in faster-growing categories.
There is also a useful market psychology angle here. MDT has often been viewed as a lower-volatility, income-oriented healthcare stock. Its beta is 0.632, which fits that reputation. So when a stock with that profile delivers better growth and stronger guidance, the market can rerate it quickly. The move is not just about a beat. It is about changing the label on the box.
Medtronic also has a solid recent earnings pattern. It beat EPS estimates in seven straight quarters before this report, according to the earnings history provided. That consistency does not guarantee future upside, of course. Still, it helps explain why investors were ready to reward another strong quarter instead of fading it.
The actionable takeaway is that Medtronic (MDT) now has a cleaner growth case than it did a day ago. A company with a 3.83% yield, a 20.6 P/E, and $5.4B in free cash flow is already attractive to investors who want stability. Add 6.75% to 7.25% expected organic growth and strong momentum in cardiac ablation, and the stock starts to look more like a quality compounder than a sleepy defensive name.
There is still context to keep in mind. MDT remains well below its 52-week high of $104.699, even after today's rise, though it is now moving away from its 52-week low of $73.31. That leaves room for further recovery if the company keeps proving that growth is broad, durable, and tied to share gains in strategic categories.
Analyst sentiment also shows a market that was constructive before the print. The consensus rating is Buy, with 26 Buy ratings, 22 Hold ratings, and no Sell ratings. The consensus target is $105.58. Those targets are not a catalyst by themselves, and one Mizuho note on June 3 lowered its target to $100. However, the real driver today is the earnings report, and the stock's move says investors found the results more persuasive than any cautious target tweak.
In short, MDT's rally is rooted in hard numbers: stronger revenue, better-than-guided earnings, solid cash flow, faster growth in cardiac ablation, and a healthy FY2027 outlook. When a large-cap medtech name delivers that package on a day when the broader market is under pressure, traders tend to notice and long-term investors tend to take a second look.
Medtronic (MDT) rises today because its June 3 earnings report gave investors a concrete reason to pay up: growth improved, guidance stayed strong, and the dividend moved higher again. For investors, the message is simple: MDT is no longer trading only on defense, and that change can matter if this growth run continues.
MDT is up because Medtronic reported fiscal Q4 and full-year FY2026 results that beat guidance, with revenue growth and earnings both coming in strong. Investors also reacted positively to upbeat FY2027 guidance, a dividend increase, and rapid growth in cardiac ablation.
+Should I buy MDT stock now?
The article suggests MDT looks more attractive after the earnings reset because it combines solid growth, a 3.83% dividend yield, and strong free cash flow. That said, investors should still weigh valuation and whether the company can sustain this faster growth trend.
+What was the main catalyst for Medtronic's rally?
The main catalyst was Medtronic’s June 3 earnings report. The company posted strong Q4 and FY2026 results, raised its outlook for FY2027, and showed especially strong momentum in Cardiac Ablation Solutions.
+Is Medtronic still a dividend stock?
Yes. Medtronic raised its quarterly dividend to $0.72 per share, extending its long streak of annual dividend increases. The stock still offers income appeal alongside its improving growth profile.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on MDT?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
